Related Experiment Video

Updated: Mar 29, 2026

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.7K

MS4322 is a selective protein arginine methyltransferase 5 degrader with antitumor effects in cervical cancer cells

Rui Luo1, Jingping Chen2, Zhaojie Chen1

  • 1Department of Obstetrics and Gynecology, Linyi People's Hospital, Shandong Second Medical University, Linyi, Shandong 276000, P.R. China.

Oncology Reports
|March 27, 2026
PubMed

Insights

MS4322, a novel agent targeting Protein arginine methyltransferase 5 (PRMT5), effectively reduced cervical cancer cell growth and spread. This targeted therapy shows promise for treating cervical cancer by inhibiting the PRMT5/Wnt/β-catenin pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cervical cancer is a common female malignancy requiring effective therapies.
  • Protein arginine methyltransferase 5 (PRMT5) is a validated oncogenic target in cervical cancer.
  • Developing targeted agents like PRMT5 degraders is crucial for improved treatment outcomes.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of MS4322, a PRMT5-specific degrader, against cervical cancer.
  • To elucidate the molecular mechanisms underlying MS4322's anti-tumor activity.
  • To assess MS4322's impact on cervical cancer cell proliferation, migration, invasion, and apoptosis.

Main Methods:

  • In vitro assays including Cell Counting Kit-8, clone formation, wound healing, and Transwell assays were performed on HeLa cells.
  • Flow cytometry, immunofluorescence staining, and immunohistochemistry were used to analyze cellular effects.
  • Small interfering RNA (siRNA) assays and Western blotting were employed to investigate molecular pathways.

Main Results:

  • PRMT5 expression is elevated in cervical cancer tissues and promotes cancer cell proliferation.
  • MS4322 treatment significantly inhibited PRMT5 mRNA expression, proliferation, migration, invasion, and clone formation in HeLa cells.
  • MS4322 induced G0/G1 cell cycle arrest and apoptosis, and inactivated the Wnt/β-catenin pathway by modulating key proteins.

Conclusions:

  • MS4322 demonstrates significant anti-tumor effects in cervical cancer models.
  • The mechanism involves the downregulation of PRMT5 and the inactivation of the Wnt/β-catenin signaling pathway.
  • MS4322 represents a promising therapeutic candidate for cervical cancer treatment.
Keywords:
MS4322Wnt/β‑catenin signaling pathwayantitumorarginine methyltransferase 5cervical cancer cell

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
In vitro Methylation Assay to Study Protein Arginine Methylation10:01

In vitro Methylation Assay to Study Protein Arginine Methylation

Published on: October 5, 2014

15.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K